Phase Ib/II Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma
Conditions: Bladder Cancer Interventions: Drug: Tislelizumab combined with two predefined dose groups of palbociclib; Drug: RP2D dose Of Tislelizumab combined with palbociclib was selected for phase II clinical trial. Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Hospitals | Neoadjuvant Therapy | Research